Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Market Insight, Epidemiology and Market Forecast - 2028
This report can be delivered to the clients within 7-10 Business Days
DelveInsight's 'Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Market Insight, Epidemiology and Market Forecast - 2028' report provides a detailed analysis of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) epidemiology and market outlook for the 7MM.
MARKETS COVERED
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Understanding and Treatment Algorithm
The market report provides the overview of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Epidemiology
The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Product Profiles & Analysis
The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Market Outlook
The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) market.
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Market Share by Therapies
This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Report Insights
DelveInsight's 'Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Market Insight, Epidemiology and Market Forecast - 2028' report provides a detailed analysis of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) epidemiology and market outlook for the 7MM.
MARKETS COVERED
- United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Understanding and Treatment Algorithm
The market report provides the overview of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Epidemiology
The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Product Profiles & Analysis
The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Market Outlook
The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) market.
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Market Share by Therapies
This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.
Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Report Insights
- Patient Population in Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
- Therapeutic Approaches in Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Pipeline Analysis
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Market Size and Trends
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Market Opportunities
- Impact of upcoming Therapies in Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
- Current Treatment Practices in Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
- Unmet Needs in Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
- Market Attractiveness
- Market Drivers and Barriers
- The report will help to develop Business Strategies by understanding the trends shaping and driving the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) market
- Organize sales and marketing efforts by identifying the best opportunities for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) market
- To understand the future market competition in the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) market.
1. REPORT INTRODUCTION
2. FAMILIAL AMYLOID POLYNEUROPATHY (TRANSTHYRETIN AMYLOIDOSIS, CORINO DE ANDRADE'S DISEASE) MARKET OVERVIEW AT A GLANCE
2.1. Market Share Distribution of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in 2016
2.2. Market Share Distribution of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in 2028
3. DISEASE BACKGROUND AND OVERVIEW: FAMILIAL AMYLOID POLYNEUROPATHY (TRANSTHYRETIN AMYLOIDOSIS, CORINO DE ANDRADE'S DISEASE)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in 7MM
4.3. Total Prevalent Patient Population of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in 7MM – By Countries
5. EPIDEMIOLOGY OF FAMILIAL AMYLOID POLYNEUROPATHY (TRANSTHYRETIN AMYLOIDOSIS, CORINO DE ANDRADE'S DISEASE) BY COUNTRIES
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.1.3. Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.1.4. Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.1.5. Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.1.6. Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.4.3. Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.4.4. Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.4.5. Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.4.6. Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.5.3. Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.5.4. Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.5.5. Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.5.6. Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.6.3. Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.6.4. Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.6.5. Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.6.6. Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.7.3. Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.7.4. Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.7.5. Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.7.6. Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.8.3. Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.8.4. Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.8.5. Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.8.6. Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.9.3. Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.9.4. Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.9.5. Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.9.6. Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
6. CURRENT TREATMENT & MEDICAL PRACTICES
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. UNMET NEEDS OF THE FAMILIAL AMYLOID POLYNEUROPATHY (TRANSTHYRETIN AMYLOIDOSIS, CORINO DE ANDRADE'S DISEASE)
8. MARKETED THERAPIES
8.1. Drug A: Company
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. PIPELINE THERAPIES – AT A GLANCE
10. KEY CROSS COMPETITION
11. EMERGING THERAPIES FOR FAMILIAL AMYLOID POLYNEUROPATHY (TRANSTHYRETIN AMYLOIDOSIS, CORINO DE ANDRADE'S DISEASE)
11.1. Drug C: Company
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. FAMILIAL AMYLOID POLYNEUROPATHY (TRANSTHYRETIN AMYLOIDOSIS, CORINO DE ANDRADE'S DISEASE): 7MM MARKET ANALYSIS
12.1. 7MM Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
12.2. 7MM Percentage Share of drugs marketed for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
12.3. 7MM Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Products
13. FAMILIAL AMYLOID POLYNEUROPATHY (TRANSTHYRETIN AMYLOIDOSIS, CORINO DE ANDRADE'S DISEASE): COUNTRY-WISE MARKET ANALYSIS
13.1. United States
13.1.1. Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States
13.1.2. Percentage Share of drugs marketed for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States
13.1.3. Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany
13.2.1.2. Percentage Share of drugs marketed for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany
13.2.1.3. Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France
13.2.2.2. Percentage Share of drugs marketed for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France
13.2.2.3. Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy
13.2.3.2. Percentage Share of drugs marketed for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy
13.2.3.3. Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain
13.2.4.2. Percentage Share of drugs marketed for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain
13.2.4.3. Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United Kingdom
13.2.5.3. Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan
13.3.2. Percentage Share of drugs marketed for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan
13.3.3. Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. MARKET DRIVERS
15. MARKET BARRIERS
16. APPENDIX
17. REPORT METHODOLOGY
17.1. Sources
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT
Indication Specific
2. FAMILIAL AMYLOID POLYNEUROPATHY (TRANSTHYRETIN AMYLOIDOSIS, CORINO DE ANDRADE'S DISEASE) MARKET OVERVIEW AT A GLANCE
2.1. Market Share Distribution of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in 2016
2.2. Market Share Distribution of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in 2028
3. DISEASE BACKGROUND AND OVERVIEW: FAMILIAL AMYLOID POLYNEUROPATHY (TRANSTHYRETIN AMYLOIDOSIS, CORINO DE ANDRADE'S DISEASE)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in 7MM
4.3. Total Prevalent Patient Population of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in 7MM – By Countries
5. EPIDEMIOLOGY OF FAMILIAL AMYLOID POLYNEUROPATHY (TRANSTHYRETIN AMYLOIDOSIS, CORINO DE ANDRADE'S DISEASE) BY COUNTRIES
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.1.3. Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.1.4. Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.1.5. Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.1.6. Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.4.3. Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.4.4. Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.4.5. Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.4.6. Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.5.3. Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.5.4. Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.5.5. Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.5.6. Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.6.3. Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.6.4. Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.6.5. Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.6.6. Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.7.3. Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.7.4. Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.7.5. Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.7.6. Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.8.3. Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.8.4. Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.8.5. Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.8.6. Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.9.3. Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.9.4. Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.9.5. Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
5.9.6. Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
6. CURRENT TREATMENT & MEDICAL PRACTICES
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. UNMET NEEDS OF THE FAMILIAL AMYLOID POLYNEUROPATHY (TRANSTHYRETIN AMYLOIDOSIS, CORINO DE ANDRADE'S DISEASE)
8. MARKETED THERAPIES
8.1. Drug A: Company
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. PIPELINE THERAPIES – AT A GLANCE
10. KEY CROSS COMPETITION
11. EMERGING THERAPIES FOR FAMILIAL AMYLOID POLYNEUROPATHY (TRANSTHYRETIN AMYLOIDOSIS, CORINO DE ANDRADE'S DISEASE)
11.1. Drug C: Company
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. FAMILIAL AMYLOID POLYNEUROPATHY (TRANSTHYRETIN AMYLOIDOSIS, CORINO DE ANDRADE'S DISEASE): 7MM MARKET ANALYSIS
12.1. 7MM Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
12.2. 7MM Percentage Share of drugs marketed for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)
12.3. 7MM Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Products
13. FAMILIAL AMYLOID POLYNEUROPATHY (TRANSTHYRETIN AMYLOIDOSIS, CORINO DE ANDRADE'S DISEASE): COUNTRY-WISE MARKET ANALYSIS
13.1. United States
13.1.1. Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States
13.1.2. Percentage Share of drugs marketed for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States
13.1.3. Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany
13.2.1.2. Percentage Share of drugs marketed for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany
13.2.1.3. Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France
13.2.2.2. Percentage Share of drugs marketed for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France
13.2.2.3. Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy
13.2.3.2. Percentage Share of drugs marketed for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy
13.2.3.3. Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain
13.2.4.2. Percentage Share of drugs marketed for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain
13.2.4.3. Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United Kingdom
13.2.5.3. Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan
13.3.2. Percentage Share of drugs marketed for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan
13.3.3. Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. MARKET DRIVERS
15. MARKET BARRIERS
16. APPENDIX
17. REPORT METHODOLOGY
17.1. Sources
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT
Indication Specific
LIST OF TABLES
Table 1: Total Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in 7MM
Table 2: Total Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States (2016-2028)
Table 6: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States (2016-2028)
Table 7: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany (2016-2028)
Table 11: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany (2016-2028)
Table 12: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France (2016-2028)
Table 14: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France (2016-2028)
Table 15: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France (2016-2028)
Table 16: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France (2016-2028)
Table 17: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy (2016-2028)
Table 21: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy (2016-2028)
Table 22: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain (2016-2028)
Table 26: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain (2016-2028)
Table 27: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in UK (2016-2028)
Table 30: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in UK (2016-2028)
Table 31: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in UK (2016-2028)
Table 32: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan (2016-2028)
Table 36: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan (2016-2028)
Table 37: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Table 42:7MM- Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Table 45: United States-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Table 48: Germany-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Table 51: France-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Table 54: Italy-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Table 57: Spain-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Table 60:UK-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Table 63: Japan-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 1: Total Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in 7MM
Table 2: Total Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States (2016-2028)
Table 6: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States (2016-2028)
Table 7: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany (2016-2028)
Table 11: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany (2016-2028)
Table 12: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France (2016-2028)
Table 14: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France (2016-2028)
Table 15: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France (2016-2028)
Table 16: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France (2016-2028)
Table 17: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy (2016-2028)
Table 21: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy (2016-2028)
Table 22: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain (2016-2028)
Table 26: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain (2016-2028)
Table 27: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in UK (2016-2028)
Table 30: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in UK (2016-2028)
Table 31: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in UK (2016-2028)
Table 32: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan (2016-2028)
Table 36: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan (2016-2028)
Table 37: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Table 42:7MM- Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Table 45: United States-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Table 48: Germany-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Table 51: France-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Table 54: Italy-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Table 57: Spain-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Table 60:UK-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Table 63: Japan-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
LIST OF FIGURES
Figure 1: Total Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States (2016-2028)
Figure 7: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany (2016-2028)
Figure 12: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France (2016-2028)
Figure 15: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France (2016-2028)
Figure 16: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France (2016-2028)
Figure 17: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy (2016-2028)
Figure 22: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain (2016-2028)
Figure 27: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in UK (2016-2028)
Figure 31: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in UK (2016-2028)
Figure 32: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan (2016-2028)
Figure 37: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Figure 42:7MM- Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Figure 45: United States-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Figure 48: Germany-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Figure 51: France-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Figure 54: Italy-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Figure 57: Spain-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Figure 60:UK-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Figure 63: Japan-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 1: Total Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States (2016-2028)
Figure 7: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany (2016-2028)
Figure 12: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France (2016-2028)
Figure 15: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France (2016-2028)
Figure 16: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France (2016-2028)
Figure 17: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy (2016-2028)
Figure 22: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain (2016-2028)
Figure 27: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in UK (2016-2028)
Figure 31: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in UK (2016-2028)
Figure 32: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan (2016-2028)
Figure 37: Treatable Cases of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Figure 42:7MM- Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Figure 45: United States-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Figure 48: Germany-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Figure 51: France-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Figure 54: Italy-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Figure 57: Spain-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Figure 60:UK-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) in USD MM (2016-2028)
Figure 63: Japan-Market Share Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) by Therapies in USD MM (2016-2028)
